240 related articles for article (PubMed ID: 23532638)
41. Diffuse and canalicular patterns of glypican-3 expression reflect malignancy of hepatocellular carcinoma.
Kawaida M; Yamazaki K; Tsujikawa H; Fukuma M; Abe Y; Kitago M; Shinoda M; Kitagawa Y; Sakamoto M
Pathol Int; 2019 Mar; 69(3):125-134. PubMed ID: 30729617
[TBL] [Abstract][Full Text] [Related]
42. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
43. Soluble cluster of differentiation 26/soluble dipeptidyl peptidase-4 and glypican-3 are promising serum biomarkers for the early detection of Hepatitis C virus related hepatocellular carcinoma in Egyptians.
Gomaa SH; Abaza MM; Elattar HA; Amin GA; Elshahawy DM
Arab J Gastroenterol; 2020 Dec; 21(4):224-232. PubMed ID: 32891543
[TBL] [Abstract][Full Text] [Related]
44. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.
Montalbano M; Rastellini C; McGuire JT; Prajapati J; Shirafkan A; Vento R; Cicalese L
Cell Oncol (Dordr); 2018 Apr; 41(2):169-184. PubMed ID: 29204978
[TBL] [Abstract][Full Text] [Related]
45. Reevaluation of glypican-3 as a prognostic marker in HCC using X-tile software.
Pan C; Wang X; Chen W; Tao C; Xu X; Jin L; Chen Y; Zhu L; Zhou L; Pan Z
Med Oncol; 2015 Jan; 32(1):359. PubMed ID: 25432695
[TBL] [Abstract][Full Text] [Related]
46. Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis.
Xiao WK; Qi CY; Chen D; Li SQ; Fu SJ; Peng BG; Liang LJ
BMC Cancer; 2014 Feb; 14():104. PubMed ID: 24548704
[TBL] [Abstract][Full Text] [Related]
47. Fucosylated fraction of alpha-fetoprotein as a predictor of prognosis in patients with hepatocellular carcinoma after curative treatment.
Tamura Y; Igarashi M; Suda T; Wakai T; Shirai Y; Umemura T; Tanaka E; Kakizaki S; Takagi H; Hiasa Y; Onji M; Aoyagi Y
Dig Dis Sci; 2010 Jul; 55(7):2095-101. PubMed ID: 19731025
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
49. Serum antibody titers against hepatitis C virus and postoperative intrahepatic recurrence of hepatocellular carcinoma.
Uemura M; Sasaki Y; Yamada T; Gotoh K; Eguchi H; Yano M; Ohigashi H; Ishikawa O; Imaoka S
Ann Surg Oncol; 2014 May; 21(5):1719-25. PubMed ID: 24464342
[TBL] [Abstract][Full Text] [Related]
50. [Expression of glypican-3, hepatocyte antigen, alpha-fetoprotein, CD34 and CD10 in hepatocellular carcinoma: a clinicopathologic analysis of 375 cases].
Du JL; Wang YL; Shi HY; Guo AT; Wei LX
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):309-13. PubMed ID: 22883669
[TBL] [Abstract][Full Text] [Related]
51. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma.
Maki A; Kono H; Gupta M; Asakawa M; Suzuki T; Matsuda M; Fujii H; Rusyn I
Ann Surg Oncol; 2007 Mar; 14(3):1182-90. PubMed ID: 17195915
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathological features and outcomes of young patients with hepatocellular carcinoma after hepatectomy.
Takeishi K; Shirabe K; Muto J; Toshima T; Taketomi A; Maehara Y
World J Surg; 2011 May; 35(5):1063-71. PubMed ID: 21380583
[TBL] [Abstract][Full Text] [Related]
53. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma.
Hyeon J; Ahn S; Lee JJ; Song DH; Park CK
Dig Dis Sci; 2013 Jul; 58(7):1916-22. PubMed ID: 23456506
[TBL] [Abstract][Full Text] [Related]
54. Risk factors for early recurrence of HBV-related hepatocellular carcinoma meeting milan criteria after curative resection.
Zhu WJ; Huang CY; Li C; Peng W; Wen TF; Yan LN; Li B; Wang WT; Xu MQ; Yang JY; Jiang L
Asian Pac J Cancer Prev; 2013; 14(12):7101-6. PubMed ID: 24460258
[TBL] [Abstract][Full Text] [Related]
55. Expression of DBC1 is associated with poor prognosis in hepatitis virus-related hepatocellular carcinoma.
Ha SY; Kim JH; Yang JW; Bae H; Cho HY; Park CK
Pathol Res Pract; 2016 Jul; 212(7):616-21. PubMed ID: 27083241
[TBL] [Abstract][Full Text] [Related]
56. Expression of glioma-associated oncogene 2 (Gli 2) is correlated with poor prognosis in patients with hepatocellular carcinoma undergoing hepatectomy.
Zhang D; Cao L; Li Y; Lu H; Yang X; Xue P
World J Surg Oncol; 2013 Jan; 11():25. PubMed ID: 23356443
[TBL] [Abstract][Full Text] [Related]
57. Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma.
Ye CP; Qiu CZ; Huang ZX; Su QC; Zhuang W; Wu RL; Li XF
World J Gastroenterol; 2007 Dec; 13(46):6264-8. PubMed ID: 18069771
[TBL] [Abstract][Full Text] [Related]
58. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.
Tremosini S; Forner A; Boix L; Vilana R; Bianchi L; Reig M; Rimola J; Rodríguez-Lope C; Ayuso C; Solé M; Bruix J
Gut; 2012 Oct; 61(10):1481-7. PubMed ID: 22287594
[TBL] [Abstract][Full Text] [Related]
59. Role of glypican-3 immunocytochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver utilizing fine needle aspiration cytology.
Zaakook M; Ayoub M; Sinna EA; El-Sheikh S
J Egypt Natl Canc Inst; 2013 Dec; 25(4):173-80. PubMed ID: 24207089
[TBL] [Abstract][Full Text] [Related]
60. Combination of osteopontin with peritumoral infiltrating macrophages is associated with poor prognosis of early-stage hepatocellular carcinoma after curative resection.
Zhu W; Guo L; Zhang B; Lou L; Lin Z; Zhu X; Ren N; Dong Q; Ye Q; Qin L
Ann Surg Oncol; 2014 Apr; 21(4):1304-13. PubMed ID: 24366422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
